At a glance
Somatropin-related research on growth hormone and its downstream effects.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Findings in people with established growth hormone deficiency do not establish the same benefit-risk balance in healthy adults. Formulation-specific instructions remain essential.[7][7][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of HGH 191AA.
Source-reported adverse effects and cautions
Note: While research in healthy athletes showed GH increased lean body mass, it did not significantly improve muscle strength or exercise performance in systematic reviews[8]. Side effects and benefits are dose-dependent, with higher doses yielding more pronounced effects but also increased risk profiles.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10IU · 2 source tables
Standard / Gradual Titration (3 mL = ~1.11 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 200 mcg | 18 units (0.18 mL) |
| Week 2 | 300 mcg | 27 units (0.27 mL) |
| Week 3 | 400 mcg | 36 units (0.36 mL) |
| Week 4 | 500 mcg | 45 units (0.45 mL) |
| Week 5 | 600 mcg | 54 units (0.54 mL) |
| Week 6 | 700 mcg | 63 units (0.63 mL) |
| Week 7 | 800 mcg | 72 units (0.72 mL) |
| Week 8 | 900 mcg | 81 units (0.81 mL) |
Frequency: Inject once daily subcutaneously, preferably at bedtime to mimic physiological GH secretion[2]. Rotate injection sites to prevent lipoatrophy[3]. This 8-week protocol represents a conservative approach with gradual dose escalation by approximately 100 mcg per week.
Extended 12-Week Protocol (Optional)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 9 | 1000 mcg | 90 units (0.90 mL) |
| Week 10 | 1100 mcg | 99 units (0.99 mL) |
| Week 11 | 1200 mcg | 108 units (1.08 mL) |
| Week 12 | 1300 mcg | 117 units (1.17 mL) |
Note: The 12-week extension reaches higher daily doses (1000–1300 mcg) that have been explored in performance and metabolic research settings[4]. These doses yield more significant physiological effects but also increase the potential for side effects. Further extension to 16 weeks (reaching 1700 mcg daily) may be considered in advanced protocols, though such aggressive regimens should be undertaken with appropriate monitoring.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support increases in lean body mass, reductions in adipose tissue, and enhanced metabolic function[7][7].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired for advanced protocols).
- Dose Range: Conservative: 150–500 mcg daily[1]; Advanced: 1000–2000 mcg daily[4].
- Reconstitution: 3.0 mL per 3.33 mg vial (~1.11 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 200 mcg daily; increase by ~100 mcg each week as tolerated.
- Conservative Target: 400–900 mcg daily by Weeks 4–8[1][7].
- Advanced Target: 1000–1300 mcg daily by Weeks 9–12 (performance/metabolic research protocols)[4].
- Frequency: Once per day (subcutaneous), preferably at bedtime[2].
- Cycle Length: 8–12 weeks standard; optional extension to 16 weeks with appropriate monitoring.
- Timing: Evening or bedtime administration preferred; rotate injection sites systematically[3].
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake vigorously to preserve protein structure)[5].
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and bioactivity.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for several weeks when stored properly[5].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- Critical: Avoid freeze–thaw cycles of reconstituted peptide, as freezing can denature the protein[5].
Injection Technique
Subcutaneous injection guidance from clinical best-practice resources[9][9].
- Clean the vial stopper and injection site with alcohol; allow to air dry completely.
- Pinch a skinfold at the injection site; insert the needle at 45–90° into subcutaneous tissue[9].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
- Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy and lipoatrophy[3][10].
- Common subcutaneous sites: abdomen (at least 2 inches from navel), outer thighs, upper arms (posterior surface)[9].
- Wait a few seconds after injection before withdrawing needle to minimize solution leakage.
Materials & quantity planning
Source materials checklist · 10IU
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (HGH 191AA, 10 IU / 3.33 mg each):
- 8 weeks ≈ 10 vials
- 12 weeks ≈ 19 vials
- 16 weeks ≈ 32 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
- 16 weeks (32 vials): 96 mL → 10 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 06
Public health resource
U.S. Food and Drug Administration: Genotropin Prescribing Information (2025) – Official label describing 191-amino-acid somatropin as a lyophilized powder for subcutaneous injection after product-specific reconstitution. (opens in a new tab)www.accessdata.fda.gov
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best practices for injection: asepsis, preparation, and administration techniques (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.